Role of antimullarian hormone in the diagnosis of sonographically inconclusive polycystic ovary syndrome

Antimullarian hormone (AMH) is found to be a vital tool for the diagnosis of polycystic ovary syndrome (PCOS). AMH may help in the diagnosis of sonographically inconclusive cases of PCOS. This study measured the AMH level in PCOS to assess its impacts on the diagnosis of the syndrome. This cross-sectional study included 160 newly diagnosed females with PCOS who were diagnosed using a modified revised Rotterdam criteria. Fasting blood was collected to measure AMH by enzyme-linked immunosorbent assay and other hormones [total testosterone, luteinizing hormone and follicle-stimulating hormone] were measured by chemiluminescent microparticle immunoassay. Ovarian USG was done in the follicular phase of the menstrual cycle. Serum AMH≥ 3.5 ng/mL and ovarian volume >10 mL was considered as a combined marker of polycystic ovary (PCO). USG-PCO criteria could detect 84.38% PCO, whereas AMH-PCO criteria 67.5%. There was a lack of agreement between USG-PCO and AMH-PCO criteria [κ=-0.004] in PCOS. AMH-PCO criteria identified 68% of PCO patients undiagnosed by USG-PCO criteria [17/25]. Age [β=-0.172, p=0.040], systolic [β =-0.213, p=0.037] and diastolic blood pressure [β=0.301, p=0.004] had significant predictive associations with AMH by linear regression. AMH had a fair discriminating index for combined-PCO [AUC=0.824] in PCOS patients. In conclusion, AMH assessment can help detect PCOS patients who are inconclusively diagnosed by USG-PCO criteria. BSMMU J 2022; 15(2): 65-69